NCT06358950Phase 2Completed

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

Study sponsor: Alkermes, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-06-19Actual
Enrollment · participants92Actual
Source updated2026-06-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview